替罗非班治疗急性冠脉综合征疗效观察

目的观察替罗非班治疗不稳定型心绞痛及急性非ST段抬高心肌梗死的临床疗效及安全性。方法68例符合高危不稳定心绞痛或急性非ST段抬高心肌梗死的患者随机分为替罗非班组（治疗组36例）和对照组（32例），所有入选患者入院后均给予阿司匹林、氯吡格雷、低分子肝素钠等药物。治疗组患者在上述治疗的基础上，加替罗非班，始0．4μg/（kg·min）静脉泵入，30min后减为0．1μg／（kg·min）维持48h。观察两组心绞痛症状、12导联心电图、1周主要心脏事件及不良反应发生情况。结果治疗组心绞痛症状、心电图ST段或T波改善等方面较对照组均有显著好转，1周内新发心肌梗死及心源性死亡等不良事件下降，无严重不良反应。结论替罗非班治疗不稳定型心绞痛及急性非ST段抬高心肌梗死是安全、有效的。

Clinical Effects of Tirofiban on the Patients with Unstable Angina and Acute Non-ST-segment Elevation Myocardial Infarction

Objective To observe the clinical effects and safety of tirofiban on the patients with unstable angina/acute non-ST-segment elevation myocardial infarction. Methods 68 high-risk patients with anstable ungina/acute non-ST-segment elevat/on myocardial infarction were randomly divided into treatment group（n=36） and contrast group（n=32）.The treatment group received tirofiban （at 0.4 μg/（kg·min） with bolus intravenous injection for 30 min,followed continueous infusion at 0.1μg/（kg·min）for 48 hours） on the basis of contrast group treatment which received aspirin, clopidorel, low molecular heprin, etc.the changes of ECG, symptoms control, the primary composite end point events and adverse drug effects were observed. Results Compared with contrast group,the tirofiban group had a significant improvement of ECG （ST-elegment/T wave）, a decrease of primary composite end point events such as cardiac shock or acute newly myocardial infarction. There was no significant adverse drug effect in two groups. Conclusion As a new antiplatelet drug,tirofiban is effective and safe for patients with unstable angina/acute non-ST-segment elevation myocardial infarction.